Novel Microbial Engraftment Trajectories Following Microbiota Transplant Therapy in Ulcerative Colitis
By
Daphne Moutsoglou
Aneesh Syal
Sharon Lopez
Elizabeth C Nelson
Lulu Chen
Amanda J Kabage
Monika Fischer
Alexander Khoruts
Byron P Vaughn
Christopher Staley
September 6, 2024
Clinical Scorecard: Emerging Patterns of Microbial Engraftment After Microbiota Transplant Therapy in Patients with Ulcerative Colitis
At a Glance
Category Detail
Condition Ulcerative colitis (UC) Key Mechanisms Engraftment of donor microbiota following microbiota transplant therapy (MTT) using encapsulated oral delivery Target Population Patients with mild-to-moderate ulcerative colitis Care Setting Outpatient clinical trial setting with daily oral capsule administration
Key Highlights
MTT with encapsulated donor microbiota capsules significantly increased donor microbial engraftment at week 12 compared to placebo. SourceTracker is an effective and reliable method to quantify donor microbiota engraftment and identify engrafting taxa in UC patients. Engraftment kinetics in UC differ from those in recurrent Clostridioides difficile infection, indicating a distinct ecological recovery pattern. Guideline-Based Recommendations
Diagnosis
Diagnosis of UC should be established prior to consideration of MTT. Management
Administer daily encapsulated microbiota transplant therapy (MTP-101C) for 8 weeks in mild-to-moderate UC patients. Consider placebo-controlled protocols to evaluate efficacy and engraftment. Monitoring & Follow-up
Monitor microbial engraftment using SourceTracker analysis of amplicon sequence data at baseline, during treatment, and post-treatment (week 12). Assess microbial diversity indices (Shannon, Chao1) and beta-diversity metrics (Bray–Curtis similarity) to correlate with engraftment. Risks
No specific risks detailed in the source material; standard clinical trial safety monitoring applies. Patient & Prescribing Data
Mild-to-moderate ulcerative colitis patients enrolled in a randomized controlled trial.
Encapsulated MTT capsules (MTP-101C) administered daily for 8 weeks resulted in higher donor microbiota engraftment at week 12 compared to placebo.
Clinical Best Practices
Use SourceTracker as a quantitative tool to assess donor microbiota engraftment and identify specific engrafting taxa. Employ repeated administration of donor microbiota via encapsulated oral capsules for sustained engraftment. Consider baseline microbial diversity indices as potential predictors of engraftment success. Follow patients for at least 4 weeks post-treatment to evaluate persistence of engraftment. References
